Evidence map›Paper›PMID 29075285›Full record

ReviewFrontiers in genetics2017

Epigenetics in the Eye: An Overview of the Most Relevant Ocular Diseases.

Hanan A Alkozi, Rafael Franco, Jesús J Pintor

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Role of epigenetics in corneal health and disease.Progress in retinal and eye research · 2025
    Review
  9. Epigenetics in Glaucoma.Medicina (Kaunas, Lithuania) · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Changes in Class I and IIb HDACs by δ-Opioid in Chronic Rat Glaucoma Model.Investigative ophthalmology & visual science · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hanan A AlkoziDepartment of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, University Complutense of Madrid, Madrid, Spain.
Rafael FrancoDepartment of Biochemistry and Molecular Biomedicine of the University of Barcelona, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.
Jesús J PintorDepartment of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, University Complutense of Madrid, Madrid, Spain.
Universidad Complutense de Madrid · ESCentro de Investigación Biomédica en Red · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sight for mammals is one of the most appreciated senses. In humans there are several factors that contribute to the increment in all kind of eye diseases. This mini-review will focus on some diseases whose prevalence is steadily increasing year after year for non-genetic reasons, namely cataracts, dry eye, and glaucoma. Aging, diet, inflammation, drugs, oxidative stress, seasonal and circadian style-of-live changes are impacting on disease prevalence by epigenetics factors, defined as stable heritable traits that are not explained by changes in DNA sequence. The mini-review will concisely show the data showing epigenetics marks in these diseases and on how knowledge on the epigenetic alterations may guide therapeutic approaches to have a healthy eye.

Indexed as

cataractsdry eyeeye diseasesglaucomakeratoconus

Identifiers

PMID29075285
PMCPMC5643502
OpenAlexW2761118372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.